Results 1 to 10 of about 51,089 (251)

Targeting the Sarcomere: Myosin Inhibitors as the Revolutionary Game Changer in Hypertrophic Cardiomyopathy. [PDF]

Rev Cardiovasc Med
Sedaghat-Hamedani F, Kayvanpour E, Meder B.   +2 more
europepmc   +1 more source

Therapeutic Response to Myosin Inhibitor Therapy in Noonan Syndrome-Associated Obstructive Hypertrophic Cardiomyopathy. [PDF]

JACC Case Rep
Feidakis A, Nies R, Kural M, Pennig L, Winnerling N, Erger F, Pfister R, Seuthe K.   +7 more
europepmc   +1 more source

Effect of Mavacamten Therapy on Myocardial Systolic Function Assessed by 3D Echocardiography. [PDF]

JACC Case Rep
Polizzi R, Canciello G, Ordine L, Lombardi R, Esposito G, Losi MA.   +5 more
europepmc   +1 more source

Cardiac myosin inhibitors: a silver lining for an old disease

Open Heart
Satyavir Yadav, Sourabh Agstam, Sandeep Singh   +2 more
openaire   +2 more sources

Case Report: Mavacamten in mid-ventricular and apical hypertrophic cardiomyopathy-a case of targeted therapy beyond left ventricular outflow tract obstruction. [PDF]

Front Med (Lausanne)
Yang L, Dai H, Rong Y.
europepmc   +1 more source

Hemodynamic Implications After Left Ventricular Outflow Tract Obstruction Relief With Mavacamten. [PDF]

JACC Case Rep
Kitai T, Zhang J, Saku K.
europepmc   +1 more source

Evolving strategies in obstructive hypertrophic cardiomyopathy: myosin inhibitors as monotherapy compared with beta-blockers. [PDF]

Heart Fail Rev
Grupper A, Sverdlov AL, Cheema BS, Nasrollahizadeh A, Hosseini K.   +4 more
europepmc   +1 more source

Hypertrophic Obstructive Cardiomyopathy Present as Acute Myocardial Infarction in a Nonagenarian. [PDF]

JACC Case Rep
Wan X, Zhan Y, Gao Z, Sui Y, Ren J, Chen H, Chang Y, Zhang C, Wang Y.   +8 more
europepmc   +1 more source

Efficacy and safety of myosin inhibitors for symptomatic hypertrophic cardiomyopathy: systematic review and meta-analysis. [PDF]

Arch Med Sci Atheroscler Dis
Hazique M, Lohana S, Kafle S, Bhinder J, Patel KN, Basit J, Bahar AR, Kvapil J, Alraies MC.   +8 more
europepmc   +1 more source

One- and two-year structural changes of mavacamten therapy in hypertrophic obstructive cardiomyopathy: a case report with serial comprehensive CMR demonstrating continuous reverse remodelling. [PDF]

Eur Heart J Case Rep
Seuthe K, Pfister R, Schönherr CH, Kaya K, Pennig L.   +4 more
europepmc   +1 more source